Here’s Why Crispr Therapeutics AG Jumped Again in February – Fox Business
SelectScience |
Here’s Why Crispr Therapeutics AG Jumped Again in February
Fox Business Crispr Therapeutics expects to file an application with the FDA later this year that could allow the company to begin human trials before the end of 2018. New drug candidates in pre-clinical development have about a 1% chance of reaching an FDA review … Editorial Article: 7 Steps to Better Gene Editing and CRISPR technology – Special FeatureSelectScience CRISPR Therapeutics AG (CRSP) EPS Estimated At $-0.71Frisco Fastball 15752 Shares in Crispr Therapeutics AG (CRSP) Acquired by DA Davidson & CO.The Ledger Gazette |
STAT |
Biotech seeking IPO riches limited disclosure of deaths tied to therapy
STAT The FDA put Unum’s clinical trial for ACTR087 on hold for two months after two patient deaths caused by the immunotherapy. |
STAT |
A biotech seeking IPO riches delayed revealing patient deaths tied to immunotherapy
STAT rivate biotechs are like Instagram posts. The glossy, successful image they choose to share can hide darker truths. So it’s been with Unum Therapeutics, a buzzy T-cell cancer immunotherapy startup backed by a roster of powerful investors, including the … |
SelectScience |
Here’s Why Crispr Therapeutics AG Jumped Again in February
Motley Fool Crispr Therapeutics expects to file an application with the FDA later this year that could allow the company to begin human trials before the end of 2018. New drug candidates in pre-clinical development have about a 1% chance of reaching an FDA review … Editorial Article: 7 Steps to Better Gene Editing and CRISPR technology – Special FeatureSelectScience CRISPR Therapeutics AG (CRSP) EPS Estimated At $-0.71Frisco Fastball Financial Newsletter – ZacksZacks Zacks all 38 news articles » |
|
CRISPR pioneer’s lab develops system to target infections and cancer
BioNews Researchers have developed a new application for CRISPR, adapting the system to detect viral infections with high accuracy, a new study finds. When CRISPR was coupled with the enzyme Cas12a, researchers at the University of California, Berkeley, found … |
BioEdge |
After 14 years, California’s stem cell agency finally gets a royalty cheque
BioEdge Fourteen years after Californians voted an overwhelming Yes! to stem cell research, including human embryonic stem cells, and created the California Institute for Regenerative Medicine (CIRM), the agency has received its first royalty cheque. The … |